Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 380

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 380
---
ables. If we encounter delays or difficulties in securing these reagents and enzymes, sequencers or other equipment or materials, and if we cannot obtain an acceptable substitute, our operations could be interrupted, which could significantly affect our business, financial condition, results of operations and reputation. There are only a few other manufacturers that are currently capable of supplying and servicing the equipment necessary for our operations, including sequencers and various associated reagents and enzymes, and transitioning to a new supplier would be time consuming and expensive, may potentially result in interruptions in operations, could affect the performance specifications of our laboratory operations or could require that we revalidate our tests. We have other minimal suppliers for disposable laboratory materials and personal protective equipment that require renewal from time to time. These supplies come from suppliers in Argentina, and as such these pose no meaningful operational risks. Wet-Lab In addition, our wet -lab’s machinery and equipment depreciate and due to normal wear and tear could eventually become inoperable, even though we maintain insurance and preventive maintenance operations in place. If any operational hazard occurs due to breakdowns or import delays for spare parts, an alternative would be to outsource sample processing to a third party, either locally or internationally, but this could affect our competitive advantage, which is focused on efficient turnaround times and optimum result quality. All samples from our products and services are processed at our Argentine Wet -Lab, where substantially all machinery and equipment are wholly owned, as one sequencing equipment is leased from Illumina, Inc. As such, no external services are necessary for sample processing. We do not have in -housemanufacturing capabilities and do not plan to develop such capacity in the foreseeable future. Dry-Lab We rely on Amazon Web Services as our primary provider for cloud computing and data storage solutions. In our commitment to safeguarding the confidentiality and integrity of patient data, we adhere to the latest cybersecurity standards, striving to achieve the utmost level of protection. We understand that our practices are substantially compliant with the Health Insurance Portability and Accountability Act, reflecting our dedication to maintaining the security and privacy of patient information. To ensure a robust defense against potential cyber threats, we enforce stringent cybersecurity measures that apply to both our internal employees and our external partners. These precautions are designed to prevent unauthorized access, ensuring that patient data remains secure and confidential across all points of interaction. 199 We also apply internal solutions to patients’ bioinformatic pipelines using open -sourcesoftware. For specific and key tasks, we trust external partners. For example, to produce the final report for Heritas